TCG Crossover
Overview
TCG Crossover is a healthcare investment firm that invests in both private and public companies developing disruptive medicines and better treatment options for patients.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Obsidian Therapeutics | Apr 2026 | Private Equity | Co-investor |
| Ollin Biosciences | Jun 2026 | Series B | Lead |
| LB Pharmaceuticals Inc | Sep 2025 | IPO | Co-investor |
| Pathalys Pharma | Aug 2024 | Series B | Co-investor |
| Adcendo | Apr 2026 | Series C | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is TCG Crossover based?
TCG Crossover is headquartered in Palo Alto, California, United States.
When was TCG Crossover founded?
TCG Crossover was founded in 2021.
How many portfolio companies does TCG Crossover have?
TCG Crossover has 8 portfolio companies in Caplight's dataset.
What are some companies in TCG Crossover's portfolio?
Portfolio companies visible on Caplight include Obsidian Therapeutics, Ollin Biosciences, LB Pharmaceuticals Inc, Pathalys Pharma, Adcendo.
What was TCG Crossover's most recent investment shown here?
TCG Crossover's most recent investment in this portfolio sample was in Ollin Biosciences in 2026.
What sectors does TCG Crossover focus on?
TCG Crossover focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does TCG Crossover focus on?
TCG Crossover typically invests at the Mid stage.
What is TCG Crossover's AUM?
TCG Crossover's assets under management are estimated between $3.1B and $3.1B.